J Korean Neurol Assoc > Volume 27(2); 2009 > Article
Journal of the Korean Neurological Association 2009;27(2): 163-169.
근위축성측삭경화증 환자에서 자가 골수유래 중간엽줄기세포치료의 유효성 및 안전성
김현영, 백진영a 박희경 최미란b 윤현수c 김경숙a 김승현
한양대학교 의과대학 신경과학교실, 코아스템a, 한양대학교 과학기술대학 분자생물과학부b, 한양대학교 의과대학 해부세포생물학교실
Efficacy and Safety of Autologous Bone Marrow-derived Mesenchymal Stem Cell Treatment in Patients With Amyotrophic Lateral Sclerosis
Hyun Young Kim
Department of Neurology, College of Medicine, Hanyang University Hospital, Seoul, Korea; Bioengineering Institute, CoreStem Inc., Seoul, Koreaa; Division of Molecular and Life Sciences, Hanyang University, Ansan, Koreab; Department of Anatomy and Cell Biology, College of Medicine, Hanyang University, Seoul, Koreac
Abstract
Background: This study was performed to investigate the efficacy and safety of intrathecal autologous bone marrowderived mesenchymal stem cells (MSCs) treatment for patients with ALS.
Methods: After a lead-in period for 3 months, 22 patients were treated with MSCs twice at an interval of 1 month. After initial MSCs injection, all patients were followed up for 3 months and their disease course, clinical characteristics were assessed. Disease status of patients were analyzed with ALS functional rating scale-revised (ALSFRS-R) for primary outcome measure, and additional clinical findings after treatment were all collected for secondary outcome measure and safety. Age and disease-duration matched patients with ALS were selected as a control group.
Results: During the follow-up period, MSCs treatment yielded a significant lesser change of ALSFRS-R score, compared to control group (1.54 vs 3.56, p<0.01). Moreover, the slop of decline of ALSFRS-R was significantly lower during the follow-up period, compared to the lead-in period in MSCs treatment group (2.68 vs 1.54, p=0.04), whereas the slopes during the two periods were not different in the control group (3.15 vs 3.56, p=0.37). MSCs treatment was well tolerated except for occurrences of transient headache, low back pain, and myalgia.
Conclusions: Our results show that intrathecal MSCs injection can slow disease progression and might be used as a disease modifying modality as an alternative treatment choice in patients with ALS. Key Words: Autologous bone marrow-derived mesenchymal stem cell, Amyotrophic lateral sclerosis, Efficacy, Safety


ABOUT
BROWSE ARTICLES
EDITORIAL POLICY
FOR CONTRIBUTORS
Editorial Office
(ZIP 03163) #1111, Daeil Bldg, 12, Insadong-gil, Jongno-gu, Seoul, Korea
Tel: +82-2-737-6530    Fax: +82-2-737-6531    E-mail: jkna@neuro.or.kr                

Copyright © 2024 by Korean Neurological Association.

Developed in M2PI

Close layer